Abstract
In 2020, cancer screenings declined, then rebounded, resulting in a cancer screening deficit. The significance of this deficit, however, has yet to be quantified from a population health perspective. Our study addresses this evidence gap by examining how the pandemic changed the timing of American adults’ most recent cancer screen. We obtained population-based, cancer screening data from the Behavioral Risk Factor Surveillance System. Mammograms, pap smears, and colonoscopies were each specified as a variable of mutually exclusive categories to indicate the timing since the most recent screening (never, 0-1 years, 1-2 years, 3+ years). Our quasi-experimental design restricts the sample to adults surveyed in January, February, or March. We then leverage a quirk in the BRFSS implementation and consider adults surveyed in the second year of each survey wave as the quasi-treatment cohort. Next, we constructed Linear and Logistic regression models which control for exogenous sociodemographic characteristics, state fixed effects, and temporal trends. Our results suggest that the deficit in 2020 was largely due to a one year delay among adults who receive annual screening, as the proportion of adults reporting a cancer screen in the past year declined by a nearly identical proportion of adults reporting their most recent cancer screen 1-2 years ago (3% to 4% points). However, the relative change was higher for mammograms and pap smears (17%) than colonoscopies (4%). We also found some evidence that the proportion of women reporting never having completed a mammogram declined in 2020, but the mechanisms for this finding should be further explored with the release of future data. Our estimates for the pandemic’s effect on cancer screening rates are smaller than prior studies, but because we account for temporal trends we believe prior studies overestimated the effect of the pandemic and underestimated the overall downward trend in cancer screenings across the country leading up to 2020.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Change format. Remove duplicate citation.
Data Availability
BRFSS data is publicly available from CDC. The analytical code to create the dataset, clean/code variables, and replicate the analysis are included in this submission.
